How do you ensure that the FDA advisory panels crucial to the drug approval process have the right members?
ACSH advisor Dr. David Shlaes, the former head of infectious disease research at Wyeth, addresses these issues especially as they relate to antibiotic panels in his recent thought-provoking entry entitled Conflict of Interest vs. Competent Advice.